A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

This is an open-label, Phase 1 study to determine the safety, tolerability, and efficacy of APL-4098 alone, and in combination with azacitidine, and in combination with azacitidine plus venetoclax for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)/AML and MDS-excess blasts (EB).

Trial Details

NCT ID
NCT06372717
Phase
PHASE1
Sponsor
Apollo Therapeutics Ltd
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • APL-4098
  • Azacitidine and APL-4098
  • Azacitidine and Venetoclax and APL-4098
Locations (sample)
  • Clayton, Victoria, Australia|-37.91667,145.11667
  • Fitzroy, Victoria, Australia|-37.79839,144.97833
  • Melbourne, Victoria, Australia|-37.814,144.96332
  • Nedlands, Western Australia, Australia|-31.98184,115.8073
  • Perth, Western Australia, Australia|-31.95224,115.8614

Key Eligibility Criteria

  • 18 years or older
  • Confirmed diagnosis of acute myeloid leukemia (R/R AML), myelodysplastic syndrome (MDS)/ AML, or MDS-excess blasts (MDS-EB) with the following char…
  • WBC count ≤ 25,000/microliter
  • ECOG Performance Status of ≤ 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →